Dream Finders Homes Raises All-Cash Bid for Beazer Homes to $32 Per Share
Beazer’s board previously rejected lower bids.
Already have an account? Sign in.
Beazer’s board previously rejected lower bids.
Chemomab and Scipher Medicine announce merger to develop nebokitug, a first-in-class anti-CCL24 antibody, in an AI-driven Phase 2 trial for rheumatoid arthritis. $30M new funding secured.
Strong Cloud revenue outlook and narrower Taobao losses drove the surge, lifting the Hang Seng Tech Index 5%.
Despite the bearish call, analyst consensus sits near $53 with a Hold rating.